Saturday October 31, 2020

State advised that skin cancer drug is 'not cost-effective'

The health service has been advised against funding a treatment for advanced skin cancer.

Susan Mitchell

Deputy Editor and Health Editor

@susmitchellsbp
15th September, 2012

The health service has been advised against funding a treatment for advanced skin cancer.

The National Centre for Pharmacoeconomics (NCPE), which carries out cost-effectiveness studies on new medicines in Ireland, concluded that the drug, Zelboraf, did not represent value for money.

Zelboraf, which is manufactured by Roche, costs €57,000 per year and blocks the effect of a mutation in a gene called BRAF. About half of patients with melanoma have this genetic mutation, which spurs...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 10 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 5 years ago